10 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 14 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 10, Terminated 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Multiple Endocrine Neoplasia: new trials by email Literature Review of Multiple Endocrine Neoplasia trials Research Report on Multiple Endocrine Neoplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FOsfomycin for Male Urinary Tract Infection Fosfomycun-trometamol - Urinary Tract Infection, Prostatitis | Phase 3 | Not yet recruiting | University Hospital, Rouen | 138 | 2026-07-01 | 2026-06-12 |
| Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors 18F-FCH, NeuroEXPLORER - Primary Hyperparathyroidism, Parathyroid Cancer | Phase 2 / Phase 3 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 193 | 2026-04-16 | 2026-10-29 |
| Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Evolocumab, Placebo - Coronary Heart Disease (CHD) | Phase 3 | Completed | Amgen | 12301 | 2019-06-11 | 2026-06-25 |
| A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer Alectinib, Crizotinib - Neoplasms | Phase 3 | Completed | Hoffmann-La Roche | 50 | 2017-07-05 | 2026-10-09 |
| A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Ribociclib, letrozole - Breast Cancer | Phase 3 | Terminated | Novartis Pharmaceuticals | 8 | 2017-06-07 | 2020-05-28 |
| Effect of PROGRESSive Training and Teststerone in Older Frail Men testosterone, Progressive muscle training - Muscle Weakness | Phase 2 / Phase 3 | Completed | University Hospital, Gentofte, Copenhagen | 192 | 2016-11-01 | 2024-05-29 |
| HIV & Drug Abuse Prevention for South African Men Soccer League (SL), Soccer League/Vocational Training (SL-V) - Substance-Related Disorders, Human Immunodeficiency Virus | Phase 3 | Completed | University of California, Los Angeles | 1211 | 2016-05-01 | 2020-02-17 |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Fulvestrant, Alpelisib, Placebo - Breast Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 572 | 2015-07-23 | 2025-02-13 |
| Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Ribociclib, Fulvestrant, Placebo - Advanced Breast Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 726 | 2015-06-09 | 2023-11-30 |
| Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility Erythromycin, Placebo, Magnetic Resonance Imaging - Healthy | Phase 2 / Phase 3 | Completed | Mayo Clinic | 40 | 2011-06-01 | 2016-03-21 |
| Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis Timed intercourse, Microsurgical varicocelectomy, Intrauterine insemination - Pregnancy, Infertility | Phase 3 | Terminated | Yale University | 3 | 2010-05-01 | 2013-07-02 |
| Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis 60 mg denosumab, Placebo - Low Bone Mass, Low Bone Mineral Density | Phase 3 | Completed | Amgen | 242 | 2009-10-01 | 2018-10-17 |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism Parathyroid hormone testing, Serum calcium testing - Hypercalcemia, Familial Primary Hyperparathyroidism | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 25 | 2006-05-09 | 2017-07-02 |
| Effectiveness of HIV Risk Reduction Program Among African American Men Focus on the Future, Control standard of care treatment - Sexually Transmitted Diseases, HIV | Phase 3 | Completed | Richard Crosby | 270 | 2003-04-01 | 2013-12-16 |
Multiple Endocrine Neoplasia Type 1 (12) · Breast Neoplasms (3) · Neoplasms (3) · Multiple Endocrine Neoplasia Type 2a (2) · Acquired Immunodeficiency Syndrome (1) · Alcoholism (1) · Bone Diseases, Metabolic (1) · Breast Diseases (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Coronary Disease (1) · Cystitis (1) · Gastrinoma (1) · Hypercalcemia (1) · Hyperparathyroidism 1 (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Endocrine Gland Neoplasms (14) · Endocrine System Diseases (14) · Genetic Diseases, Inborn (14) · Neoplasms, Multiple Primary (14) · Neoplastic Syndromes, Hereditary (14) · Neoplasms by Site (13) · Neoplasms (11) · Genital Diseases (4) · Urogenital Diseases (4) · Infections (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Breast Diseases (2)
Fulvestrant (2) · ribociclib (2) · Alpelisib (1) · Autogenic Training (1) · Crizotinib (1) · Denosumab (1) · Erythromycin (1) · Letrozole (1) · Magnetic Resonance Spectroscopy (1) · Sodium Chloride (1) · Surgical Procedures, Operative (1) · Testosterone (1) · Water (1) · alectinib (1) · evolocumab (1)
Novartis Pharmaceuticals (3) · Amgen (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Hoffmann-La Roche (1) · Mayo Clinic (1) · Richard Crosby (1) · University Hospital, Gentofte, Copenhagen (1) · University Hospital, Rouen (1) · University of California, Los Angeles (1) · Yale University (1)
United States (9) · France (5) · Italy (4) · Russia (4) · South Korea (4) · Spain (4) · Australia (3) · Austria (3) · Belgium (3) · Bulgaria (3) · Canada (3) · Czechia (3) · Denmark (3) · Germany (3) · Hungary (3)
Andrew Forsythe, PhD (1) · Christos Coutifaris, MD (1) · Dana A Ohl, MD (1) · Esther Eisenberg, MD, MPH (1) · Gregory M Christman, MD (1) · Heping Zhang, PhD (1) · Jeff Fidler, MD (1) · Karsten Overgaard, M.D. (1) · Mary Jane Rotheram, PhD (1) · Michael Diamond, MD (1) · Nanette Santoro, MD (1)
PMID 22130101, PMID 29500160, PMID 29860922, PMID 30075740, PMID 30653530, PMID 31091374, PMID 31305131, PMID 31826360, PMID 32106835, PMID 32416251, PMID 33246021, PMID 33769862, PMID 33780274, PMID 34102253, PMID 34158598, PMID 36380117, PMID 36800111, PMID 37653397, PMID 37673211, PMID 38439079, PMID 39177931, PMID 39259241, PMID 39289825, PMID 39826197, PMID 41211925, PMID 41903215, PMID 42153665, PMID 42183757, PMID 42334791, PMID 42663360, PMID 42670293
2015 (2), 2023 (2), 2017 (1), 2018 (1), P01DK068055 (1), R01DA038675 (1), R21MH066682 (1), U10HD055925 (1), U10HD055936 (1)